Seer, Inc. ((SEER)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Seer, Inc. Earnings Call: A Cautiously Optimistic Outlook
The recent earnings call for Seer, Inc. painted a picture of cautious optimism, with the company showcasing significant achievements alongside notable challenges. The call highlighted strong revenue growth, successful product launches, and strategic partnerships, which were slightly tempered by issues such as decreased gross margins, high operating expenses, and external economic pressures. Overall, the sentiment was positive, with an optimistic outlook prevailing.
Strong Revenue Growth
Seer, Inc. reported impressive revenue figures for the second quarter of 2025, with $4.1 million in revenue, marking a 32% year-over-year growth. This growth was supported by a robust balance sheet, boasting $263 million in cash, cash equivalents, and investments, underscoring the company’s financial stability.
Launch of Proteograph ONE
A key highlight of the earnings call was the launch of the Proteograph ONE workflow. This innovation more than doubled throughput and reduced run time by approximately 30%, enabling the identification of up to 10 times more proteins than traditional workflows, marking a significant advancement in the field.
Landmark Study with Korea University
Seer announced a groundbreaking 20,000 sample population scale study with Korea University. This study, the largest of its kind, leverages advanced proteomics for early cancer detection, showcasing the scalability and impact of Seer’s technology.
Share Repurchase Program
The company has been actively executing its share repurchase program, having repurchased approximately $20 million of its Class A common shares. This move has reduced the net total shares outstanding by approximately 13%, reflecting confidence in the company’s future prospects.
Strong Customer Validation
Seer continues to receive strong validation from its customers, with 52 publications in high-impact journals highlighting the unique capabilities of the Proteograph technology. This level of validation underscores the growing recognition and acceptance of Seer’s innovations.
Gross Margin Pressure
Despite the positive developments, Seer faced gross margin pressure, with margins decreasing to 52% from 56% in the previous year. This decline was attributed to higher costs related to instrument installation and training.
Operating Expenses and Loss
The company reported total operating expenses of $22.6 million, resulting in a net loss of $19.4 million for the second quarter of 2025. These figures highlight the financial challenges that Seer is navigating as it continues to invest in its growth.
Macroeconomic and Policy Headwinds
Seer is also contending with macroeconomic and policy headwinds, including uncertainty around government funding, evolving tariffs, and broader macroeconomic volatility. These factors are impacting customer purchasing decisions and pose ongoing challenges.
Forward-Looking Guidance
During the earnings call, Seer provided forward-looking guidance, reaffirming its full-year 2025 revenue target of $17 million to $18 million, representing a 24% growth at the midpoint compared to 2024. The company remains committed to its $25 million share repurchase program and anticipates reaching cash flow breakeven with its current financial resources. The launch of the Proteograph ONE workflow and the landmark study with Korea University were highlighted as key drivers of future growth.
In conclusion, Seer, Inc.’s earnings call reflected a cautiously optimistic outlook, with strong revenue growth and innovative product launches being tempered by financial challenges and macroeconomic pressures. The company’s strategic initiatives and forward-looking guidance suggest a promising path ahead, despite the hurdles it faces.